Taking statins in combination with a key antibody could reduce cholesterol levels even further new research suggests.
The 12-week study showed patients who took the monoclonal antibody Evolocumab alongside moderate to high intensity statin therapy were able to reduce the amount of “bad cholesterol” in their blood.
Patients were randomly assigned to a daily moderate or high intensity statin therapy for four weeks. They were then either given Evolocumab, a placebo or Ezetimibe in addition to their statin treatment to test out whether this had any extra effect on cutting cholesterol levels.
Statins are a drug which lower the levels of “bad cholesterol” your body makes which can lead to fatty deposits in your arteries.
Our Senior Cardiac Nurse Julie Ward, said: “Having high levels of LDL or ‘bad’ cholesterol in our bloodstream increases the risk of developing cardiovascular disease and having a heart attack or stroke.
It is also worth remembering the other ways we can try and lower our cholesterol levels
“Statins are proven to be effective in reducing bad cholesterol levels and the risk of heart attack and stroke, but some patients still need extra treatment options as this research suggests.
“However, this was a relatively short study so further research needs to be carried out to assess the safety of these additional treatments in lowering cholesterol.
“It is also worth remembering the other ways we can try and lower our cholesterol levels. Lifestyle changes like stopping smoking, eating healthily and getting plenty of exercise all play a crucial role in keeping our cholesterol levels in check.”